
Medtronic (MDT) Stock Forecast & Price Target
Medtronic (MDT) Analyst Ratings
Bulls say
Medtronic is expected to see continued growth and increased earnings due to its diverse portfolio, M&A strategy, and potential for expansion in its neurovascular platform. Despite competition and risks from clinical trial results, the company has been rated as a Buy with a price target of $90 based on its success with the Symplicity Spyral RDN System, upcoming separation of its Diabetes segment, and recent acquisitions and partnerships aligning with its strategy for growth.
Bears say
Medtronic is facing several potential headwinds in the near future that may negatively impact their stock performance. These include an increasingly competitive landscape in their electrophysiology (EP) segment, the risk of disruption to their transcatheter aortic valve replacement (TAVR) volumes, and the potential for margin contraction due to continued investments in recent acquisitions and a shift towards lower-margin businesses. Additionally, macroeconomic volatility, especially related to tariffs and currency fluctuations, may also pose a threat to Medtronic's global operations. With these challenges in mind, my outlook for Medtronic is negative as I believe the company may face difficulties in achieving its target EPS growth and could potentially underperform in key end markets.
This aggregate rating is based on analysts' research of Medtronic and is not a guaranteed prediction by Public.com or investment advice.
Medtronic (MDT) Analyst Forecast & Price Prediction
Start investing in Medtronic (MDT)
Order type
Buy in
Order amount
Est. shares
0 shares